Skip to main content
ASSURE TECH (HANGZHOU) CO., LTD. logo

ASSURE TECH (HANGZHOU) CO., LTD. — Investor Relations & Filings

Ticker · 688075 ISIN · CNE100004ZC0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2021-11-16 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688075

About ASSURE TECH (HANGZHOU) CO., LTD.

https://www.diareagent.com/

Assure Tech (Hangzhou) Co., Ltd. is a biotechnology enterprise specializing in the research, development, and manufacturing of in vitro diagnostic (IVD) reagents and clinical testing instruments. The company focuses on rapid diagnostic tests and Point of Care Testing (POCT) solutions across various medical fields, including infectious diseases, drug of abuse screening, oncology, cardiac markers, and fertility. Utilizing advanced lateral flow immunoassay technology, Assure Tech provides diagnostic tools designed for accuracy and efficiency in clinical and laboratory settings. The company adheres to international quality standards, maintaining ISO 13485 certification and obtaining regulatory clearances such as FDA and CE marks for its product range. Through its integrated R&D and production infrastructure, Assure Tech supplies a diverse portfolio of diagnostic products to a global customer base.

Recent filings

Filing Released Lang Actions
安旭生物公司章程
Regulatory Filings
2021-11-16 Chinese
安旭生物首次公开发行股票科创板上市公告书
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the initial public offering (IPO) and listing of Hangzhou Anxu Biotechnology Co., Ltd. on the Shanghai Stock Exchange's STAR Market (科创板). It includes extensive risk disclosures, financial data for multiple years, regulatory approvals from the China Securities Regulatory Commission (CSRC) and Shanghai Stock Exchange, stock issuance details, shareholder information, and company background. The document is titled as a "首次公开发行股票 科创板上市公告书" which translates to "Initial Public Offering and STAR Market Listing Announcement." It is not a full annual or quarterly report but a comprehensive listing prospectus or IPO announcement. The document length is substantial (15,000 characters), and it contains detailed financial and risk information related to the IPO. This type of document fits best under the category of Regulatory Filings (RNS) because it is a regulatory announcement related to the IPO and listing, not a full annual report, earnings release, or other specific report type. It is not a simple announcement of a report publication (RPA) because it contains substantive content and data. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-11-16 Chinese
安旭生物首次公开发行股票并在科创板上市发行结果公告
Capital/Financing Update Classification · 95% confidence The document is titled as an "发行结果公告" which translates to "Issuance Result Announcement" for the initial public offering (IPO) and listing of Hangzhou Anxu Biotechnology Co., Ltd. on the STAR Market (科创板). It details the results of the stock issuance, including the number of shares issued, pricing, subscription statistics, strategic placement, online and offline subscription results, underwriting details, and the lottery results for offline subscription. The document is an announcement of the outcome of a capital raising event (IPO) and does not contain financial statements or detailed financial performance data. It is not a full annual or interim report, nor an earnings release or management discussion. It is specifically an update on the capital raising and issuance results. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial and contains detailed issuance results, supporting a high confidence in this classification.
2021-11-11 Chinese
安旭生物首次公开发行股票并在科创板上市招股说明书
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus (招股说明书) for the initial public offering (IPO) and listing of Hangzhou Assure Tech Biotechnology Co., Ltd. on the Shanghai Stock Exchange STAR Market (科创板). It includes extensive information about the company, risk factors, financial data, business overview, governance, and other disclosures typical of an IPO prospectus. The document is not an annual report, earnings release, or any other type of periodic financial report. It is a formal offering document used to inform investors about the company and the stock issuance. Therefore, the filing type corresponds to a prospectus for an IPO, which aligns with the category of Capital/Financing Update (CAP) as it relates to stock issuance and listing information.
2021-11-11 Chinese
安旭生物首次公开发行股票并在科创板上市网下初步配售结果及网上中签结果公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the initial public offering (IPO) of shares by 杭州安旭生物科技股份有限公司 on the Shanghai Stock Exchange's STAR Market (科创板). It includes information about the allotment results for offline and online investors, subscription details, pricing, allocation ratios, and payment instructions. The document also references regulatory approvals and compliance with securities issuance rules. It is not a financial report like an annual or quarterly report, nor is it a transcript, audit report, or management report. It is a formal announcement of the results of a capital raising event (IPO) and the allocation of shares to investors. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a simple notice but a substantive update on financing activity.
2021-11-09 Chinese
安旭生物首次公开发行股票并在科创板上市网上发行申购情况及中签率公告
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding the initial public offering (IPO) of shares by 杭州安旭生物科技股份有限公司 on the Shanghai Stock Exchange's STAR Market (科创板). It details the subscription situation, allocation results, pricing, and the lottery process for share allotment. It includes specific dates, share quantities, pricing, underwriting details, and subscription rules. The document is not a full financial report, audit, or earnings release, but rather a detailed announcement of the IPO subscription and allocation results. This fits the category of Capital/Financing Update (CAP), which covers company fundraising and capital structure changes such as IPOs.
2021-11-08 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.